NasdaqCM:EYES

Stock Analysis Report

Second Sight Medical Products

Executive Summary

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Second Sight Medical Products has significant price volatility in the past 3 months.
  • Second Sight Medical Products is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Second Sight Medical Products's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.6%

NasdaqCM:EYES

-0.6%

US Medical Equipment

-1.0%

US Market


1 Year Return

-47.4%

NasdaqCM:EYES

14.5%

US Medical Equipment

-0.4%

US Market

EYES underperformed the Medical Equipment industry which returned 13.7% over the past year.

EYES underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

EYESIndustryMarket
7 Day-3.6%-0.6%-1.0%
30 Day-11.0%0.4%-3.3%
90 Day-9.5%10.1%0.4%
1 Year-47.4%-47.4%15.5%14.5%1.8%-0.4%
3 Year-77.6%-77.6%67.0%61.8%39.4%30.4%
5 Yearn/a131.4%104.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Second Sight Medical Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Second Sight Medical Products undervalued based on future cash flows and its price relative to the stock market?

4.76x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Second Sight Medical Products to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Second Sight Medical Products to establish if it is available at substantial discount.


Price Based on Earnings

Second Sight Medical Products is loss making, we can't compare its value to the US Medical Equipment industry average.

Second Sight Medical Products is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Second Sight Medical Products, we can't assess if its growth is good value.


Price Based on Value of Assets

Second Sight Medical Products is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Second Sight Medical Products expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

3.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Second Sight Medical Products's revenue is expected to grow significantly at over 20% yearly.

Second Sight Medical Products is not considered high growth as it is expected to be loss making for the next 1-3 years.

Second Sight Medical Products's revenue growth is expected to exceed the United States of America market average.

Unable to compare Second Sight Medical Products's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Second Sight Medical Products's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Second Sight Medical Products will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Second Sight Medical Products performed over the past 5 years?

-4.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Second Sight Medical Products does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Second Sight Medical Products's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Second Sight Medical Products's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Second Sight Medical Products has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Second Sight Medical Products has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Second Sight Medical Products improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Second Sight Medical Products's financial position?


Financial Position Analysis

Second Sight Medical Products is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Second Sight Medical Products's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Second Sight Medical Products has no debt.

Second Sight Medical Products currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Second Sight Medical Products has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Second Sight Medical Products has less than a year of cash runway based on current free cash flow.

Second Sight Medical Products has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.5% each year.


Next Steps

Dividend

What is Second Sight Medical Products's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Second Sight Medical Products's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Second Sight Medical Products's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Second Sight Medical Products has not reported any payouts.

Unable to verify if Second Sight Medical Products's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Second Sight Medical Products has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Second Sight Medical Products's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Jonathan McGuire (56yo)

4.0yrs

Tenure

US$1,225,105

Compensation

Mr. Jonathan Will McGuire has been the President, Chief Executive Officer and Director at Second Sight Medical Products, Inc. since August 18, 2015. Mr. McGuire was President of Americas Commercial at Volc ...


CEO Compensation Analysis

Jonathan's remuneration is higher than average for companies of similar size in United States of America.

Jonathan's compensation has increased whilst company is loss making.


Management Age and Tenure

1.3yrs

Average Tenure

55.5yo

Average Age

The average tenure for the Second Sight Medical Products management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.3yrs

Average Tenure

61yo

Average Age

The tenure for the Second Sight Medical Products board of directors is about average.


Insider Trading

Second Sight Medical Products individual insiders have only sold shares in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$16,64904 Jun 19
Edward Randolph
EntityIndividual
Shares23,586
Max PriceUS$0.71
BuyUS$11,15529 Apr 19
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares12,051
Max PriceUS$0.93
BuyUS$21,28023 Apr 19
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares22,914
Max PriceUS$0.95
BuyUS$13,49916 Apr 19
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares12,543
Max PriceUS$1.08
BuyUS$25,26212 Apr 19
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares23,725
Max PriceUS$1.07
BuyUS$25,26212 Apr 19
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares23,725
Max PriceUS$1.07
BuyUS$1,499,99614 Dec 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares1,637,550
Max PriceUS$0.92
BuyUS$1,499,99614 Dec 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares1,637,550
Max PriceUS$0.92
SellUS$3,84104 Dec 18
Edward Randolph
EntityIndividual
Shares3,733
Max PriceUS$1.03
SellUS$7,98904 Dec 18
Stephen Okland
EntityIndividual
Role
Chief Commercial Officer
Shares7,764
Max PriceUS$1.03
BuyUS$1,998,85822 Oct 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares1,233,863
Max PriceUS$1.62
BuyUS$1,998,86022 Oct 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares1,233,864
Max PriceUS$1.62
BuyUS$8,41016 Oct 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares4,994
Max PriceUS$1.68
BuyUS$8,41016 Oct 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares4,994
Max PriceUS$1.68
BuyUS$23,37609 Oct 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares13,385
Max PriceUS$1.79
BuyUS$21,57104 Oct 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares12,038
Max PriceUS$1.81
BuyUS$26,95220 Sep 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares14,808
Max PriceUS$1.87
BuyUS$14,20718 Sep 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares7,937
Max PriceUS$1.79
BuyUS$9,12918 Sep 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares5,100
Max PriceUS$1.79
BuyUS$13,25612 Sep 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares7,938
Max PriceUS$1.67
BuyUS$13,25512 Sep 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares7,937
Max PriceUS$1.67
BuyUS$26,02205 Sep 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares15,414
Max PriceUS$1.70
BuyUS$13,74101 Sep 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares7,938
Max PriceUS$1.73
BuyUS$13,73901 Sep 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares7,937
Max PriceUS$1.73
BuyUS$23,89930 Aug 18
Sam B Williams 1995 Generation-Skipping Trust
EntityCompany
Shares14,930
Max PriceUS$1.61
BuyUS$16,15621 Aug 18
Gregg Williams
EntityIndividual
Role
Chairman of the Board
Shares9,992
Max PriceUS$1.63

Ownership Breakdown


Management Team

  • Jonathan McGuire (56yo)

    CEO, President & Director

    • Tenure: 4.0yrs
    • Compensation: $1.23m
  • Steve Okland (55yo)

    Chief Commercial Officer

    • Tenure: 1.3yrs
    • Compensation: $615.76k
  • Gunnar Bjorg

  • John Blake (43yo)

    CFO & Corporate Secretary

    • Tenure: 1.4yrs
    • Compensation: $1.05m
  • Pat Ryan (58yo)

    Chief Operating Officer

    • Tenure: 0.9yrs
    • Compensation: $914.24k

Board Members

  • Bill Link (73yo)

    Independent Director

    • Tenure: 16.6yrs
    • Compensation: $91.25k
  • Matt Pfeffer (61yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: $88.59k
  • Aaron Mendelsohn (67yo)

    Independent Director

    • Tenure: 21.6yrs
    • Compensation: $74.26k
  • Gregg Williams (60yo)

    Non-Executive Chairman

    • Tenure: 1.4yrs
    • Compensation: $84.01k
  • Jonathan McGuire (56yo)

    CEO, President & Director

    • Tenure: 4.0yrs
    • Compensation: $1.23m

Company Information

Second Sight Medical Products, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Second Sight Medical Products, Inc.
  • Ticker: EYES
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: health care equipment
  • Sector: healthcare
  • Market Cap: US$100.915m
  • Shares outstanding: 124.59m
  • Website: Click here

Number of Employees


Location

  • Second Sight Medical Products, Inc.
  • 12744 San Fernando Road
  • Suite 400
  • Sylmar
  • California
  • 91342
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EYESNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2014
24PDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 00:35
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.